No differences were observed in the prevention of necrotizing enterocolitis and late–onset sepsis among preterm infants who received either single–species or multi–species probiotics
{"title":"No differences were observed in the prevention of necrotizing enterocolitis and late–onset sepsis among preterm infants who received either single–species or multi–species probiotics","authors":"Peter Korček, Zbyněk Straňák","doi":"10.1016/j.earlhumdev.2024.106054","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Probiotic prophylaxis has been suggested to reduce the incidence of necrotizing enterocolitis (NEC) and late–onset sepsis (LOS) in very preterm newborns. However, choosing the optimal probiotic is difficult due to variations in strain–specific effects and interactions facilitated by the use of combination species.</p></div><div><h3>Aims</h3><p>To compare clinical outcomes of very preterm infants receiving multi or single–species probiotics.</p></div><div><h3>Study design</h3><p>Retrospective, single–center, cohort study.</p></div><div><h3>Subjects</h3><p>Very preterm infants (<32 weeks' gestation) born between 2019 and 2022 at a tertiary perinatal center received either a multi–species (<em>Lactobacillus rhamnosus</em> 45 %, <em>Lactobacillus casei</em> 15 %, <em>Lactobacillus acidophilus</em> 15 %, <em>Bifidobacterium infantis</em> 15 %, <em>Bifidobacterium bifidum</em> 10 %; <em>n</em> = 228) or a single–species (<em>Bifidobacterium breve</em> BR03 and B632; <em>n</em> = 227) probiotic formulation.</p></div><div><h3>Main outcome measures</h3><p>NEC, LOS, and mortality.</p></div><div><h3>Results</h3><p>The overall incidence of NEC and LOS was 3.1 % and 13.8 %, respectively. There were no differences between the multi–species and single–species probiotic groups in the rate of NEC (3.5 % vs 2.6 %; <em>p</em> = 0.787), LOS (15.4 % vs 12.3 %; <em>p</em> = 0.416), mortality (0.9 % vs 1.8 %; <em>p</em> = 0.449), or composite outcome (NEC, LOS and/or death; 16.7 % vs 12.8 %; <em>p</em> = 0.290).</p></div><div><h3>Conclusion</h3><p>The clinical outcomes of very preterm newborns receiving multi vs. single–species probiotic formulations were similar in our study. In view of the sample size and low baseline rate of NEC in our unit, further trials are warranted to investigate the effects of specific probiotics for prevention of serious neonatal morbidities.</p></div>","PeriodicalId":11435,"journal":{"name":"Early human development","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Early human development","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0378378224001233","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Probiotic prophylaxis has been suggested to reduce the incidence of necrotizing enterocolitis (NEC) and late–onset sepsis (LOS) in very preterm newborns. However, choosing the optimal probiotic is difficult due to variations in strain–specific effects and interactions facilitated by the use of combination species.
Aims
To compare clinical outcomes of very preterm infants receiving multi or single–species probiotics.
Study design
Retrospective, single–center, cohort study.
Subjects
Very preterm infants (<32 weeks' gestation) born between 2019 and 2022 at a tertiary perinatal center received either a multi–species (Lactobacillus rhamnosus 45 %, Lactobacillus casei 15 %, Lactobacillus acidophilus 15 %, Bifidobacterium infantis 15 %, Bifidobacterium bifidum 10 %; n = 228) or a single–species (Bifidobacterium breve BR03 and B632; n = 227) probiotic formulation.
Main outcome measures
NEC, LOS, and mortality.
Results
The overall incidence of NEC and LOS was 3.1 % and 13.8 %, respectively. There were no differences between the multi–species and single–species probiotic groups in the rate of NEC (3.5 % vs 2.6 %; p = 0.787), LOS (15.4 % vs 12.3 %; p = 0.416), mortality (0.9 % vs 1.8 %; p = 0.449), or composite outcome (NEC, LOS and/or death; 16.7 % vs 12.8 %; p = 0.290).
Conclusion
The clinical outcomes of very preterm newborns receiving multi vs. single–species probiotic formulations were similar in our study. In view of the sample size and low baseline rate of NEC in our unit, further trials are warranted to investigate the effects of specific probiotics for prevention of serious neonatal morbidities.
期刊介绍:
Established as an authoritative, highly cited voice on early human development, Early Human Development provides a unique opportunity for researchers and clinicians to bridge the communication gap between disciplines. Creating a forum for the productive exchange of ideas concerning early human growth and development, the journal publishes original research and clinical papers with particular emphasis on the continuum between fetal life and the perinatal period; aspects of postnatal growth influenced by early events; and the safeguarding of the quality of human survival.
The first comprehensive and interdisciplinary journal in this area of growing importance, Early Human Development offers pertinent contributions to the following subject areas:
Fetology; perinatology; pediatrics; growth and development; obstetrics; reproduction and fertility; epidemiology; behavioural sciences; nutrition and metabolism; teratology; neurology; brain biology; developmental psychology and screening.